|1.||Geijtenbeek, Teunis B H: 24 articles (07/2014 - 03/2002)|
|2.||van Kooyk, Yvette: 23 articles (03/2014 - 03/2002)|
|3.||Rojo, Javier: 14 articles (08/2015 - 12/2003)|
|4.||Fieschi, Franck: 14 articles (03/2015 - 11/2002)|
|5.||Pöhlmann, Stefan: 13 articles (04/2013 - 08/2002)|
|6.||Amara, Ali: 11 articles (04/2014 - 11/2002)|
|7.||Neyrolles, Olivier: 10 articles (07/2010 - 01/2003)|
|8.||Bernardi, Anna: 9 articles (03/2015 - 07/2007)|
|9.||Corbí, Angel L: 9 articles (02/2011 - 03/2002)|
|10.||Gicquel, Brigitte: 9 articles (11/2007 - 01/2003)|
09/01/2006 - "A better understanding of the role of DC-SIGN in HIV-1 infection may help to design novel therapeutic strategies against the progression of HIV-1 disease in the drug-using population."
10/01/2005 - "The dendritic cell-specific ICAM-3-grabbing nonintegrin (DC-SIGN) homolog, SIGN-related 1 (SIGNR1) is a pathogen receptor expressed by splenic marginal zone and peritoneal macrophages, and is essential for clearance of Streptococcus pneumoniae by phagocytosis after intraperitoneal infection. "
01/01/2012 - "This study provides compelling evidence to support an important role of DC-SIGN in IU HIV-1 infection."
01/01/2010 - "Furthermore, infection studies with mycobacterial strains genetically engineered to lack manLAM or PIMs demonstrated that the manLAM/PIM-DC-SIGN interaction was not critical for cytokine secretion in vitro and protective immunity in vivo. "
01/01/2009 - "Earlier studies reported that DC present at the site of infection trap virus particles via DC-SIGN and transfer the virus to the interacting naïve T cells. "
01/01/2008 - "Our present work suggests that decreased levels of the DC-SIGN receptor may therefore be protective against both clinical tuberculosis in general and cavitory tuberculosis disease in particular. "
02/01/2011 - "Previous studies have shown that the variation, especially the -871A/G and -336A/G in DC-SIGN promoter influenced the susceptibility to tuberculosis. "
11/01/2007 - "In this light, we aimed to study the potential implication of DC-SIGN genetic variation in the predisposition to tuberculosis in a group of Tunisian patients. "
11/01/2007 - "Recent studies showed that DC-SIGN is the major receptor of Mycobacterium tuberculosis on human dendritic cells and that polymorphisms in the DC-SIGN promoter region are associated with susceptibility to tuberculosis. "
10/01/2006 - "The aim of this study was to investigate the influence of DC-SIGN functional polymorphisms -336G/A SNP in the promoter region and insertion/deletion in the "neck" region on the predisposition to tuberculosis. "
|3.||HIV Infections (HIV Infection)
06/01/2005 - "A better understanding of the role of DC-SIGN in HIV infection may help to design novel therapeutic strategies against the progression of HIV disease in the drug-using population."
01/01/2016 - "Hence, these compounds can combine to inactivate the viruses and suppress DC-SIGN-mediated virus-cell interaction that as shown earlier leads to dendritic cell HIV infection and transinfection dependent on the DC-SIGN receptor. "
01/01/2016 - "An efficacious dose-dependent inhibition of DC-SIGN-mediated HIV infection in both pretreatment and posttreatment settings was observed, as indicated by inhibitory potentials (EC50) [D66 (8 μM), D06 (48 mM), HNG156 (40 μM), UM15 (100 nM), and K13 (25 nM)]. "
03/04/2015 - "Designing nanomolar antagonists of DC-SIGN-mediated HIV infection: ligand presentation using molecular rods."
04/01/2013 - "Contact of HIV-1 with DC-SIGN is thus the first event in the pathogenic cascade and, therefore, it is the primary target point for therapies aimed at HIV infection prevention. "
|4.||Premature Birth (Birth, Premature)
12/01/2010 - "Exposure to drugs of abuse during pregnancy may increase MTCT of HIV through a variety of mechanisms that are addressed in detail including possible damage to the placenta, induction of preterm birth, and increasing maternal plasma viral load though a variety of putative mechanisms such as: (a) promoting HIV replication in monocyte/macrophages; (b) increasing the expression of CCR5 receptors; (c) decreasing the expression of CCR5 receptor ligands; (d) increasing the expression of CXCR4 receptors; (e) increasing the expression of DC-SIGN; (f) impairing the efficacy of HAART through drug-drug interaction; and (g) promoting HIV mutation and replication through non-adherence to HAART."
|5.||Acquired Immunodeficiency Syndrome (AIDS)
02/01/2009 - "This study seeks to determine any relationship between HIV-AIDS immunopathology and DC-SIGN expression levels in DCs from typical, rapid, and slow progressors. "
01/01/2008 - "Evolution of DC-SIGN use revealed by fitness studies of R5 HIV-1 variants emerging during AIDS progression."
02/01/2009 - "Expression of DC-SIGN in peripheral blood dendritic cells of patients with typical, slow, and rapid progression to AIDS."
01/01/2008 - "Significantly lower levels of DC-SIGN expression were identified in spleen, mesenteric lymph node, and bone marrow of macaques with AIDS (P<0.05). "
01/01/2008 - "DC-SIGN expression was evaluated by immunohistochemistry in lymphoid tissues from AIDS-susceptible Asian macaque monkeys as compared with AIDS-resistant sooty mangabey monkeys in the presence and absence of SIV infection. "
|1.||C-Type Lectins (C-Type Lectin)
|2.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|4.||CCR5 Receptors (CCR5 Receptor)
|6.||Interleukin-6 (Interleukin 6)
|7.||CXCR4 Receptors (CXCR4 Receptor)
|8.||Street Drugs (Illicit Drugs)
|10.||mannose receptor (receptor, mannose)
|1.||Highly Active Antiretroviral Therapy (HAART)